Skip to main content
Caplight Logo









Zhejiang Xina Pharmaceutical Co., Ltd.

Zhejiang Xina Pharmaceutical Co., Ltd.

Private
ChinaHealthcare & Life Scienceshttps://xinapharma.com

Last Round

Series C

Mar 3, 2026

Est. Valuation

$555.09M

Total Funding Raised

$215.1M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Zhejiang Xina Pharmaceutical Co., Ltd. is a biotechnology company that develops innovative systemic inhalation drug delivery platforms and formulations.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

inhalation drug deliverydrug reformulationsystemic inhalationdrug delivery platformantiemetic therapyrespiratory treatmentoral inhalationdrug licensingbiotechpharma R&Ddrug delivery techCOPD treatmentmigraine treatmentdrug delivery systemsDDS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Zhejiang Xina Pharmaceutical Co., Ltd. Comparables

Compare Zhejiang Xina Pharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.

Zhejiang Xina Pharmaceutical Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Suzhou Inhal Pharma Co., Ltd.
80%
Chance Pharmaceuticals
79%
Pulmatrix, Inc.
78%

Zhejiang Xina Pharmaceutical Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMar 3, 2026
Series BJul 5, 2022
Series AMar 18, 2021

Zhejiang Xina Pharmaceutical Co., Ltd. Investors

Notable investors and investment history

Zhejiang Xina Pharmaceutical Co., Ltd. investors
InvestorRounds
MPCSeries A
盛世投资 (Shengshi Investment)Series B
Lilly Asia VenturesSeries A
State Development and Investment Group Co., Ltd.Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 3, 2026

    $94M round led by Citic Medical Fund and Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund.

  • Jul 5, 2022

    $60M round raised with participation from State Development and Investment Group Co., Ltd.

Zhejiang Xina Pharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Zhejiang Xina Pharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Zhejiang Xina Pharmaceutical Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersChina
Year Founded2019
Last FundingMar 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?